Monlutenca (Lutetium (177lu) Chloride)

Lutetium (177Lu) Chloride, the active ingredient in Monlutenca, is a radiopharmaceutical presented as a sterile solution for intravenous administration. It emits beta particles that deliver localized radiation to malignant cells, supporting targeted oncologic radiotherapy for patients with appropriate tumor types.

GNH USA supplies Monlutenca as a licensed, EU‑origin, GDP‑compliant international pharmaceutical product, serving hospitals, oncology centres, and specialty pharmacies worldwide. The company provides comprehensive logistics, including temperature‑controlled shipping where required, to meet the needs of global healthcare providers.

Monlutenca is employed in targeted radiotherapy for malignant tumors that express suitable molecular markers.

Neuroendocrine tumors: delivers targeted beta radiation to somatostatin receptor‑positive lesions, helping to control disease progression. Prostate cancer (PSMA‑positive): provides localized radiation to prostate cancer cells expressing PSMA, contributing to tumor control. Metastatic bone pain from cancer: reduces pain by irradiating bone metastases, improving patient comfort.

Monlutenca may be associated with a range of adverse reactions observed in clinical use.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: transient tiredness. - Transient hematologic changes: mild decrease in blood counts. - Injection site discomfort: local pain or erythema.

Serious or Rare Side Effects: - Severe myelosuppression: significant reduction in blood cell production. - Renal toxicity: impaired kidney function. - Radiation‑induced pneumonitis: inflammation of lung tissue. - Secondary malignancies: rare risk of new cancers.

Prior to prescribing Monlutenca, several safety considerations should be observed. - Patient selection: confirm target receptor expression before therapy. - Baseline blood work: assess hematologic parameters. - Renal function: evaluate kidney function to adjust dosing. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Concurrent chemotherapy: coordinate timing to reduce overlapping toxicity. - Store at ambient temperature: keep in original container, protect from light and moisture.

Monlutenca can interact with other agents that affect blood counts or organ function.

Major Interactions (Avoid): - Myelosuppressive chemotherapy: may cause severe bone marrow suppression. - Nephrotoxic drugs: increase risk of renal injury. - High‑dose radiation therapy: additive radiation toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for bleeding due to thrombocytopenia. - Immunosuppressants: watch for infection risk. - Radiopharmaceuticals with overlapping biodistribution: assess cumulative radiation dose.